PUNE, India, May 13, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "Psoriasis - Pipeline Review, H1 2016" marketresearch report that provides an overview of the Psoriasis's therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA)
Complete report on H1 2016 pipeline review of Psoriasis with 216 market data tables and 17 figures, spread across 771 pages is available at http://www.rnrmarketresearch.com/psoriasis-pipeline-review-h1-2016-market-report.html .
The report also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Psoriasis Pipeline Review, H1 2016 report include 3SBio Inc., 4SC AG, Abeome Corporation, AbGenomics International, Inc., ADC Therapeutics Sarl, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Affibody AB, Ajinomoto Pharmaceuticals Co., Ltd., AlbireoPharma, Almirall, S.A., Amgen Inc., Anacor Pharmaceuticals, Inc., AnaptysBio, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Athenex, Inc., Aurigene Discovery Technologies Limited, Avexxin AS, BIOCAD, Biocon Limited, BioLingus AG, BioMAS Ltd., Biomics Biotechnologies Co., Ltd., Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Creabilis SA, Crescendo Biologics Limited, Curapel Limited, Delenex Therapeutics AG, Domainex Limited, Dr. August Wolff GmbH & Co. KG Arzneimittle, Effimune SAS, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Exicure, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Galectin Therapeutics, Inc., Gem Pharmaceuticals, LLC, Gene Signal International SA, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, GliaCure Inc., GlycoMar Limited, Grupo Ferrer Internacional, S.A., Hydra Biosciences, Inc., Idera Pharmaceuticals, Inc., Immune Pharmaceuticals Inc., Immune Response BioPharma, Inc., Immungenetics AG, Innovent Biologics, Inc., Invion Limited, Jenrin Discovery, Inc., Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, LEO Pharma A/S, Lipidor AB, Lupin Limited, Mabion SA, mAbxience S.A., Maruho Co., Ltd., MediGene AG, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Neovacs SA, Nimbus Therapeutics, LLC, NovaLead Pharma Pvt. Ltd., Novan, Inc., Novartis AG, Nuevolution AB, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, PinCell srl, Polichem S.A., Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Prothena Corporation Plc, Provectus Biopharmaceuticals, Inc., RedHill Biopharma Ltd., Rigel Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Selvita S.A., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Shulov Innovative Science Ltd., Sigmoid Pharma Limited, SignPath Pharma Inc, Soligenix, Inc., Spherium Biomed S.L., Stemline Therapeutics, Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Tasly Pharmaceutical Group Co., Ltd., Telormedix SA, TetraLogic Pharmaceuticals, Teva Pharmaceutical , Industries Ltd., Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Tolero Pharmaceuticals, Inc., UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc., vTv Therapeutics LLC, Wellstat Therapeutics Corporation, Yuhan Corporation and Ziarco Pharma Ltd.
Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=542535 .
Another newly published market research report titled on Actinic (Solar) Keratosis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Actinic (Solar) Keratosis Pipeline market research report of 95 pages is available at http://www.rnrmarketresearch.com/actinic-solar-keratosis-pipeline-review-h1-2016-market-report.html .
Explore more reports on Dermatology therapeutics.
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. Tel: +1-888-391-5441 email@example.com
SOURCE RnR Market Research
Subscribe to our Free Newsletters!
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...